Serum  	Serum  	 NNP	B-NP
IL-23  	IL-23  	 NNP	I-NP
in  	in  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children  	children  	 NNS	I-NP
Asthma  	Asthma  	 NNP	I-NP
is  	is  	 VBZ	O
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
airway  	airway  	 JJ	B-NP
inflammation  	inflammation  	 NN	I-NP
that  	that  	 WDT	O
is  	is  	 VBZ	O
controlled  	controlled  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
complex  	complex  	 JJ	O
cytokine  	cytokine  	 JJ	B-NP
network 	network 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
Th1 	Th1 	 CD	B-NP
/ 	/ 	 CD	O
Th2  	Th2  	 CD	B-NP
imbalance  	imbalance  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
well  	well  	 RB	O
documented  	documented  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	I-NP
allergic  	allergic  	 JJ	I-NP
asthma 	asthma 	 NN	I-NP
.  	.  	 .	O
Recently 	Recently 	 RB	O
,  	,  	 ,	O
Th17  	Th17  	 CD	B-NP
cells  	cells  	 NNS	I-NP
and  	and  	 CC	O
regulatory  	regulatory  	 JJ	B-NP
T  	T  	 NN	I-NP
( 	( 	 -LRB-	O
Treg 	Treg 	 NNP	B-NP
)  	)  	 -RRB-	O
cells  	cells  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
found  	found  	 VBN	O
to  	to  	 TO	O
participate  	participate  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	I-NP
allergic  	allergic  	 JJ	I-NP
asthma 	asthma 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
study  	study  	 NN	O
aimed  	aimed  	 VBN	O
at  	at  	 IN	O
verifying  	verifying  	 NN	O
whether  	whether  	 IN	O
anti-inflammatory  	anti-inflammatory  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
could  	could  	 MD	O
change  	change  	 VB	O
serum  	serum  	 JJ	B-NP
IL-4 	IL-4 	 NN	I-NP
,  	,  	 ,	O
IL-10  	IL-10  	 NNP	B-NP
and  	and  	 CC	O
IL-23  	IL-23  	 CD	B-NP
in  	in  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children 	children 	 NNS	I-NP
.  	.  	 .	O
Globally 	Globally 	 RB	O
,  	,  	 ,	O
78  	78  	 CD	O
children  	children  	 NNS	O
( 	( 	 -LRB-	O
40  	40  	 CD	O
males  	males  	 NNS	O
and  	and  	 CC	O
38  	38  	 CD	O
females 	females 	 NNS	O
,  	,  	 ,	O
median  	median  	 JJ	B-NP
age  	age  	 NN	I-NP
9.3  	9.3  	 CD	O
+-  	+-  	 CD	O
3.7  	3.7  	 CD	O
years 	years 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
with  	with  	 IN	O
asthma  	asthma  	 NN	B-NP
and  	and  	 CC	O
monosensitized  	monosensitized  	 JJ	O
to  	to  	 TO	O
house  	house  	 VB	O
dust  	dust  	 NN	O
mites 	mites 	 NNS	O
,  	,  	 ,	O
were  	were  	 VBD	O
evaluated 	evaluated 	 VBN	O
.  	.  	 .	O
Lung  	Lung  	 NNP	O
function  	function  	 NN	O
( 	( 	 -LRB-	O
such  	such  	 JJ	O
as  	as  	 IN	O
FEV1 	FEV1 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
serum  	serum  	 JJ	B-NP
IL-4 	IL-4 	 NN	I-NP
,  	,  	 ,	O
IL-10  	IL-10  	 NNP	B-NP
and  	and  	 CC	O
IL-23  	IL-23  	 CD	B-NP
levels  	levels  	 NNS	I-NP
were  	were  	 VBD	O
measured  	measured  	 VBN	O
at  	at  	 IN	O
baseline  	baseline  	 NN	B-NP
( 	( 	 -LRB-	O
T0 	T0 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
after  	after  	 IN	O
4  	4  	 CD	O
weeks  	weeks  	 NNS	O
( 	( 	 -LRB-	O
T1 	T1 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
after  	after  	 IN	O
12  	12  	 CD	O
weeks  	weeks  	 NNS	O
( 	( 	 -LRB-	O
T2 	T2 	 NNP	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
inhaled  	inhaled  	 JJ	B-NP
corticosteroid  	corticosteroid  	 NNS	I-NP
( 	( 	 -LRB-	O
ICS 	ICS 	 NNP	B-NP
)  	)  	 -RRB-	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
control  	control  	 NN	B-NP
group  	group  	 NN	I-NP
consisted  	consisted  	 VBD	O
of  	of  	 IN	O
40  	40  	 CD	O
healthy  	healthy  	 JJ	O
children  	children  	 NNS	O
( 	( 	 -LRB-	O
22  	22  	 CD	O
males  	males  	 NNS	O
and  	and  	 CC	O
18  	18  	 CD	O
females 	females 	 NNS	O
)  	)  	 -RRB-	O
age  	age  	 NN	O
matched 	matched 	 VBD	O
.  	.  	 .	O
At  	At  	 IN	O
baseline 	baseline 	 NN	B-NP
,  	,  	 ,	O
IL-4  	IL-4  	 NN	B-NP
and  	and  	 CC	O
IL-23  	IL-23  	 CD	B-NP
levels  	levels  	 NNS	I-NP
were  	were  	 VBD	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
severe  	severe  	 JJ	O
asthmatics  	asthmatics  	 NN	B-NP
than  	than  	 IN	O
in  	in  	 IN	O
control  	control  	 NN	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
p  	p  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
while  	while  	 IN	O
serum  	serum  	 CD	B-NP
IL-10  	IL-10  	 CD	I-NP
levels  	levels  	 NNS	I-NP
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
lower  	lower  	 JJR	O
in  	in  	 IN	O
group  	group  	 NN	O
of  	of  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children  	children  	 NNS	I-NP
as  	as  	 RB	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
healthy  	healthy  	 JJ	O
control  	control  	 NN	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
p  	p  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
At  	At  	 IN	O
T2 	T2 	 NNP	O
,  	,  	 ,	O
IL-4  	IL-4  	 NN	B-NP
and  	and  	 CC	O
IL-23  	IL-23  	 NNP	B-NP
significantly  	significantly  	 RB	O
diminished  	diminished  	 VBN	O
( 	( 	 -LRB-	O
p  	p  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
while  	while  	 IN	O
IL-10  	IL-10  	 NNP	B-NP
significantly  	significantly  	 RB	O
increased 	increased 	 VBN	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
significant  	significant  	 JJ	O
relationship  	relationship  	 NN	B-NP
between  	between  	 IN	O
FEV1  	FEV1  	 NNP	B-NP
and  	and  	 CC	O
IL-4 	IL-4 	 NN	B-NP
,  	,  	 ,	O
IL-10  	IL-10  	 NNP	B-NP
and  	and  	 CC	O
IL-23  	IL-23  	 CD	B-NP
at  	at  	 IN	O
T0  	T0  	 NNP	O
( 	( 	 -LRB-	O
r=-0.784 	r=-0.784 	 NNP	O
;  	;  	 :	O
r=-0.735  	r=-0.735  	 CD	O
and  	and  	 CC	O
r=-0.787 	r=-0.787 	 NNP	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
correlations  	correlations  	 VBN	B-NP
between  	between  	 IN	O
FEV1  	FEV1  	 NNP	B-NP
and  	and  	 CC	O
IL-4 	IL-4 	 NN	B-NP
,  	,  	 ,	O
IL-10  	IL-10  	 NNP	B-NP
and  	and  	 CC	O
IL-23  	IL-23  	 CD	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
at  	at  	 IN	O
T1  	T1  	 NNP	O
( 	( 	 -LRB-	O
r=-0.563 	r=-0.563 	 NNP	O
;  	;  	 :	O
r=-0.539  	r=-0.539  	 CD	O
and  	and  	 CC	O
r=-0.583 	r=-0.583 	 NNP	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
at  	at  	 IN	O
T2  	T2  	 NNP	O
( 	( 	 -LRB-	O
r=-0.549 	r=-0.549 	 NNP	O
;  	;  	 :	O
r=-0.428  	r=-0.428  	 CD	O
and  	and  	 CC	O
r=-0.393 	r=-0.393 	 NNP	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 JJ	O
study  	study  	 NN	O
provided  	provided  	 VBD	B-NP
evidence  	evidence  	 NN	I-NP
that 	that 	 IN	O
:  	:  	 :	O
i 	i 	 FW	O
)  	)  	 -RRB-	O
serum  	serum  	 VBZ	B-NP
IL-23  	IL-23  	 NNP	I-NP
was  	was  	 VBD	O
up-regulated  	up-regulated  	 JJ	O
also  	also  	 RB	O
in  	in  	 IN	O
asthmatic  	asthmatic  	 JJ	B-NP
children 	children 	 NNS	I-NP
,  	,  	 ,	O
ii 	ii 	 CD	O
)  	)  	 -RRB-	O
ICS  	ICS  	 NNP	B-NP
treatment  	treatment  	 NN	I-NP
was  	was  	 VBD	O
able  	able  	 JJ	O
of  	of  	 IN	O
reducing  	reducing  	 VBG	B-NP
IL-23 	IL-23 	 NNP	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
iii 	iii 	 CD	O
)  	)  	 -RRB-	O
IL-23  	IL-23  	 CD	B-NP
change  	change  	 NN	I-NP
well  	well  	 RB	O
related  	related  	 VBN	O
with  	with  	 IN	O
lung  	lung  	 NN	O
function  	function  	 NN	O
improvement 	improvement 	 NN	O
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
presumable  	presumable  	 VBN	O
that  	that  	 IN	O
IL-23  	IL-23  	 NNP	B-NP
could  	could  	 MD	O
be  	be  	 VB	O
a  	a  	 DT	O
suitable  	suitable  	 JJ	O
marker  	marker  	 NN	O
of  	of  	 IN	O
allergic  	allergic  	 JJ	B-NP
inflammation  	inflammation  	 NN	I-NP
in  	in  	 IN	O
asthma 	asthma 	 NN	B-NP
.  	.  	 .	O
